A paclitaxel-coated balloon, Agent DCB (Boston Scientific), was superior to an uncoated balloon for treating coronary in-stent restenosis in patients undergoing percutaneous coronary intervention (PCI ...
A new drug-eluting balloon can perform just as well as the standard treatment for patients with coronary in-stent restenosis (ISR) undergoing repeated percutaneous coronary intervention (PCI). These ...
Please provide your email address to receive an email when new articles are posted on . A paclitaxel-coated balloon bested conventional angioplasty in treating coronary in-stent restenosis. The coated ...
Dr. Mehran is a co-Principal Investigator of the breakthrough "SELUTION4ISR Trial," with results presented at Transcatheter Cardiovascular Therapeutics 2025. A new drug-eluting balloon can perform ...
SAN FRANCISCO — A sirolimus-eluting balloon was found to be noninferior to conventional stenting in separate trials of patients undergoing percutaneous coronary interventions (PCIs), suggesting these ...
Over $8 billion worth of coronary stents will be sold annually by 2025, according to a new research report by Global Market Insights, Inc. The increase over the years will be created by an increase in ...
Leverages Abbott's Market-Leading MULTI-LINK Stent Design and Cobalt Chromium Alloy for the Treatment of Iliac Artery Disease Expands Abbott's Offerings of Innovative Therapies for Treatment of ...
Hosted on MSN
Drug-eluting balloon may be as safe, effective as conventional stents for repeat percutaneous coronary interventions
A new drug-eluting balloon can perform just as well as the standard treatment for patients with coronary in-stent restenosis (ISR) undergoing repeated percutaneous coronary intervention (PCI). These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback